CITIC Jiantou: The domestic cross-border e-commerce industrial chain has been gradually improved. CITIC Jiantou said that from 2010 to 2014, China's cross-border e-commerce entered a stage of rapid development. With the rise of mobile Internet infrastructure and the penetration rate of overseas cross-border e-commerce giants in the Mainland, the supporting facilities of the industrial chain have been gradually improved, subdivided and specialized, relevant policies have continued to exert their strength, and the customs supervision model has gradually become clear; Cross-border e-commerce industry chain is long, and there are relatively many hidden risk points because it involves cross-border. The cost structure of each link is mainly different due to the differences in participation roles, platform models, product types, warehousing and logistics structures, etc. Overall, the current cost structure is relatively stable, but there is also a large room for optimization. The degree of specialization and refinement of service providers will be improved, and the overall control, collaboration and empowerment of the industry chain and the refined arrangement led by big data and industry cognition will become one of the core competitiveness.Guotai Junan: It is expected that the lithium price will fluctuate in the bottom range in 2025, and there is a strong opportunity and space for rebound. Guotai Junan Securities recently reported that the lithium price has entered the bottom range by the end of 2024. If the demand maintains the current neutral estimate in 2025, the lithium price will fluctuate in the bottom range. At present, the market is optimistic about the demand in 2025, and the industry supply has slowed down. It is estimated that the price trend of lithium will fluctuate in the bottom range in 2025, in which the stage is affected by seasonal factors and there is a strong rebound opportunity and space. The market expected the trading of lithium plate earlier, that is, when the commodity price bottomed out, the lithium plate already contained the expectation of industrial clearing. When the industry actually enters the stage of supply and clearing, the sector will trade commodity price reversal expectations. From this, we infer that the rise of lithium plate will start before the spot price reverses.CITIC Jiantou: The domestic cross-border e-commerce industrial chain has been gradually improved. CITIC Jiantou said that from 2010 to 2014, China's cross-border e-commerce entered a stage of rapid development. With the rise of mobile Internet infrastructure and the penetration rate of overseas cross-border e-commerce giants in the Mainland, the supporting facilities of the industrial chain have been gradually improved, subdivided and specialized, relevant policies have continued to exert their strength, and the customs supervision model has gradually become clear; Cross-border e-commerce industry chain is long, and there are relatively many hidden risk points because it involves cross-border. The cost structure of each link is mainly different due to the differences in participation roles, platform models, product types, warehousing and logistics structures, etc. Overall, the current cost structure is relatively stable, but there is also a large room for optimization. The degree of specialization and refinement of service providers will be improved, and the overall control, collaboration and empowerment of the industry chain and the refined arrangement led by big data and industry cognition will become one of the core competitiveness.
Asiana Airlines: It is estimated that the debt ratio will drop from the previous 1847% to 700%.Yingsi Intelligent announced that it had received a milestone payment of $10 million from Exelixis. On December 13th, Yingsi Intelligent, a biomedical technology company, announced that based on the progress made in the clinical stage of XL309(ISM3091) project, the company had recently received the first clinical milestone payment from Exelixis, with a total amount of $10 million.Onlikon: The cooperative product Aidit calcitonin soft capsules is planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13th, and on December 12th, the company received a notice from its partner Beijing Meifurun Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Meifurun") that the Aidit calcitonin soft capsules jointly developed by the company and its wholly-owned subsidiary Wenzhou Haihe Pharmaceutical Co., Ltd. are planned to be selected for the tenth batch of national centralized drug procurement. According to the Pharmaceutical Cooperation Agreement signed by the company and its partner Mei Furun, the company owns 50% of the cooperative products.
Japan's short-term survey index of large-scale manufacturing industry in December reported 14, with an estimated 13.Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.Citic Jiantou Pharmaceutical's 2025 strategy: looking for new additions and integration opportunities. Citic Jiantou said that looking forward to 2025, the reform policy in the medical field has been normalized, and the most noteworthy incremental policy in the medical insurance field is to establish a diversified payment system. The medical field is about to usher in the reform of "deep water areas" such as salary system and graded diagnosis and treatment, which is in line with expectations as a whole. At the same time, the innovation of China's pharmaceutical industry has gradually stepped onto the international stage, some sub-sectors will be marginally improved, and industry integration will begin. We are optimistic about the investment opportunities in the pharmaceutical industry in 2025. It is suggested to focus on the new increase (innovation, going out to sea, marginal change) and industry integration opportunities.
Strategy guide 12-14
Strategy guide
12-14
Strategy guide
Strategy guide
12-14